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Abstract (248 words) 
Schizophrenia is a severe psychiatric disorder with strong heritability and marked heterogeneity in symptoms, 
course and treatment response. There is strong interest in identifying genetic risk factors that can help to 
elucidate the pathophysiology  and may result in the development of improved treatments. Linkage and 
genome-wide association studies (GWAS) suggest that the genetic basis of schizophrenia is heterogeneous.  
However, it remains unclear whether the underlying genetic variants are mostly moderately rare, and can be 
identified by genotyping variants observed in sequenced cases in large follow-up cohorts, or whether they will 
typically be much rarer and therefore more effectively identified by gene-based methods that seek to 
combine candidate variants. 
Here we consider 166 persons with schizophrenia or schizoaffective disorder who have had either their 
genomes or exomes sequenced to high coverage. From these data, we selected 5155 variants that were 
further evaluated in an independent cohort of 2617 cases and 1800 controls. No single variant showed a 
study-wide significant association in the initial or follow up cohorts. However, a number of case-specific 
variants were identified, some of which may be real risk factors for schizophrenia, and these can be readily 
interrogated in other datasets. Our results indicate that schizophrenia risk is unlikely to be predominantly 
influenced by variants just outside the range detectable by GWAS. Rather, multiple rarer genetic variants 
must contribute substantially to the predisposition to schizophrenia, suggesting that both very large sample 
sizes and gene based association tests will be required to securely identify genetic risk factors.  
Introduction 
Schizophrenia [MIM 181500] is characterized by positive symptoms (e.g., delusions, hallucinations, disorganized 
thinking), negative symptoms (e.g., flat affect, loss of spontaneity, diminished initiative and capacity for 
pleasure, impaired volition), numerous cognitive dysfunctions of varying severity, mood disturbances and 
suicidality. Antipsychotic drugs are usually effective in treating positive symptoms, and to a much lesser extent, 
3 
 
cognitive impairment. Clozapine, the prototypical atypical antipsychotic drug, has also been shown to uniquely 
reduce risk the risk for suicide in schizophrenia1; 2. Cognitive impairment is considered the major cause of deficits 
in functioning3, but the other components of the illness contribute as well, collectively interfering substantially 
with quality of life and constituting significant burdens on the families of individuals with schizophrenia. Genetic 
studies that implicate variants in specific genes as risk factors for the syndrome may help to elucidate the 
pathophysiology of the syndrome and the identification of novel treatment targets. 
Despite many years of study, the genetic basis of schizophrenia remains largely unknown. Many complex 
diseases, including neuropsychiatric disorders such as epilepsy and Alzheimer’s disease [MIM 104300]4; 5, have 
been shown to have Mendelian forms; however, no single gene mutations of large effect have been conclusively 
identified in schizophrenia. Moreover, genome-wide association studies (GWAS) have identified only variants 
associated with extremely small effects on risk. For example, GWAS meta-analyses on 8000 cases and 19,000 
controls identified several high frequency associations with very small odd ratios (1.1-1.3), effectively ruling out 
the possibility that risk for schizophrenia is determined primarily by a modest number of common variants (or 
even hundreds of common variants)6-8. On the other hand, studies of rare copy number variants (CNVs) have 
shown that a modest proportion of schizophrenia cases can be attributed to a heterogeneous collection of rare 
CNVs with high but incomplete penetrance, with estimated odds ratios ranging from 2.7 to 25 9-12. Because of 
their rarity, and the multiple genes involved in many of the CNV regions, they represent daunting targets for 
drug development unless they lead to more generalized downstream effects that affect a much higher 
percentage of people with schizophrenia .  
With very little of the heritability of schizophrenia explained by non-genetic causes, and good evidence for a role 
for rare variants, there is intense interest in using next generation sequencing to identify additional rare variants 
associated with schizophrenia. These, in turn, might help to identify pathways that could inform and motivate 
novel drug development efforts. Two recent studies explored the role of highly penetrant individual sequence 
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variants in schizophrenia by examining the number and function of de novo variants in apparent sporadic 
schizophrenia (in 14 and 53 cases, respectively)13; 14. The authors of both studies concluded that an excess of de 
novo variants was seen in the schizophrenia cases and, additionally, that more of these than expected were 
damaging, suggesting that at least some schizophrenia cases are caused by highly penetrant de novo variants. 
However, the high heritability of schizophrenia is not compatible with the hypothesis that most cases are the 
result of de novo mutations.   
The genetic explanation of the majority of schizophrenia cases therefore remains unresolved. One possibility not 
excluded by current evidence, is that variants only slightly below the detection threshold for GWAS have 
appreciable effects on risk (for example variants with frequencies approaching 0.5% and relative risks of 2 or 
slightly more). If there were many such variants some could be readily detected by sequencing case genomes 
and genotyping identified variants in a large cohort of additional cases. This is the design we follow here. 
Another possibility is that most pathogenic mutations have frequencies well below the GWAS detection 
threshold. For such variants, the most efficient design will be to employ screens based on the combination of 
variants across particular genes or regions. There is a clear analogy here with CNVs. Although each individual 
mutation in a schizophrenia-associated CNV region appears to have arisen either de novo or very recently, and 
thus has extremely low frequency, collectively they reach frequencies that are significantly different in cases 
versus controls 9; 10; 15-19. Whether this will be the requisite paradigm for identifying sequence variants remains to 
be resolved.  
Here we examined the first possibility – whether a substantial proportion of schizophrenia cases can be 
explained by individual, moderately rare variants with strong effects. We took a set of 5155 rare variants 
identified in 166 sequenced schizophrenia genomes and exomes, and genotyped them in an additional 
unrelated 2617 cases and 1800 controls to determine whether rare variants over-represented in unrelated cases 
relative to controls could be detected in samples of this size. 
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Methods 
Study Participants 
Discovery Cases were 166 individuals  with a diagnosis of schizophrenia or schizoaffective disorder, enriched for 
treatment resistant cases and/or cases with a strong family history. The original sequenced cases comprised 47 
Finnish individuals with schizophrenia defined as treatment-resistant (as indicated by qualifying for treatment 
with clozapine), 87 US individuals with treatment-resistant schizophrenia/ schizoaffective disorder (all whole 
exome sequenced), and 32 US individuals with a diagnosis of schizophrenia as well as a family history of 
schizophrenia or other severe neuropsychiatric disorders (whole genome sequenced). The sample was 
approximately 10% African ancestry, 89% European ancestry and 1% other (Native American, Hispanic). The 
institutional review boards (IRBs) of Duke University Medical Center and collaborating institutions approved all 
procedures. Follow-up cases (n=2756) were 544 US individuals with a family history of schizophrenia or other 
severe neuropsychiatric disorders (including 20 overlapping with whole genome sequenced for QC purposes), 
364 US samples, including 168 treatment resistant (79 overlapping with exome sequenced), 360 Italian samples, 
and 1567 samples obtained from the Rutgers repository. Follow up cases were 45% African ancestry, 54% 
European ancestry and 1% other (Hispanic, Asian, Middle Eastern). Informed consent was obtained from all 
participants or their legal guardians.  
Discovery Controls (n=307) and follow-up controls (n=1932, including 65 discovery controls for quality control 
purposes) were subjects not enriched for (but not specifically screened for) neuropsychiatric disorders enrolled 
in Duke IRB approved protocols who consented to future unrelated research, and from samples received from 
outside institutions under a Duke IRB exemption. Discovery controls were 6% African ancestry, 92% European 
6 
 
ancestry and 2% other (Hispanic, Native American, Middle Eastern). Follow-up controls were 37% African 
ancestry, 59% European ancestry and 3% other (Hispanic, Asian, Middle Eastern). 
Power Calculations were performed with Power for Genetic Association Analyses (PGA) 20. 
Targeted capture and exome/ genome sequencing. For whole exome sequencing, the target regions were 
captured using the Agilent SureSelect Human All Exon 37Mb or 50Mb Kit (Agilent Technologies, Santa Clara, CA) 
following vendor provided protocols. Sequencing was performed in the CHGV Genomic Analysis Facility, using 
either Illumina GAII or HiSeq machines. Whole genome sequencing was performed as previously described21. 
Each read was then aligned to the reference genome (NCBI human genome assembly build 36; Ensembl core 
database release 50_361 1) using the Burrows-Wheeler Alignment (BWA) tool 22 and single nucleotide variants 
(SNVs) and small insertion-deletions (indels) were identified by using SAMtools23. PCR duplicates were removed 
using the Picard software (for URL, see Web Resources).  
Variant Selection. We focused on variants annotated as functional, where functional was defined as non-
synonymous, nonsense or located in the canonical splice sites. The analysis was restricted to variants with a 
MAF< 0.05 or, for the recessive model, MAF<0.3. For each variant tested, only individuals with a minimum 
coverage of 10x at that site were included (n= 152,511 SNVs for the allelic model and 172,886 for the recessive 
model).  
We first tested for genetic association, using ATAV (for URL see Web Resources)to run Fisher’s exact tests 
comparing exome-captured regions from cases and controls. We then removed variants with greater than 50% 
of the individuals missing due to low coverage, a Hardy-Weinberg equilibrium p value < 0.001, variants with a 
p<0.05 but whose frequency was higher in controls, and those variants that were clearly driven by differences 
between the Finnish or African American subjects and the other samples. All other associated (p<0.05) variants 
were put forward for scoring in the iSelect follow-up (n=316 allelic, 206 recessive).  
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Because of an expectation of high locus heterogeneity, we recognized that a gene may play a role in only a single 
case in our sequenced samples, and so we also selected variants that formed genotypes in cases but were not 
present in controls. From this set, we removed: variants that were present in only one individual (“unique 
variants”) if that individual had greater than the mean + 1 standard deviation of unique variants (suggesting that 
these may have been poor quality calls) (n=485 allelic, 5 recessive), unique variants that were present only in the 
Finnish samples (since we had no Finnish controls) (n=293 allelic, 12 recessive) and unique variants in a low 
coverage sample (23.5-25x, n=4 samples; n=33 allelic, 1 recessive). 
We then included for scoring 1) all variants that were in an essential splice site, destroyed a stop codon or 
introduced a new stop codon (n=1643 allelic, n=43 recessive), 2) all variants in a region associated through rare 
copy number variation with epilepsy, schizophrenia, autism or intellectual disability (n=863 allelic, 2 recessive), 
and 3) all non-synonymous variants that got a PolyPhen224 rating of ‘probably damaging’ (n=3736 allelic, n=51 
recessive). These 6,860 variants were submitted to Illumina’s online Assay Design Tool to predict the likelihood 
of a successful assay. All variants with a score below 0.6 were removed, leaving 5,788 variants.  
iSelect QC. The raw data (idats) from the custom iSelect genotyping were brought into the Illumina 
GenomeStudio software. All variants were clustered using the GenomeStudio default parameters. The call rates 
were inspected and any samples with a call rate below 0.95 were removed from analysis. Each variant call was 
manually inspected for clustering accuracy and any obvious miscalls were corrected or deleted if correcting was 
not possible due to irregular clustering. Genders were checked based on X and Y chromosome variants, and 
mismatched samples were excluded. For a subset of samples, we also had Illumina genome-wide SNP array data, 
which we used to check the concordance for overlapping SNPs, and discordant samples were excluded from 
analysis. Of these 5788 variants, 5155 variants were successfully genotyped and passed all QC checks. We 
obtained genotypes for these variants in an additional 2617 cases and 1800 controls that passed all QC checks. 
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Individuals with epilepsy were also genotyped with the iselect array, and all putative schizophrenia-associated 
variants were investigated in cases with epilepsy to evaluate possible variable expressivity25.).  
Data Analysis. Because of allele frequency differences between subjects of African and European decent, we 
analyzed these two population groups separately and then, where appropriate, combined the p values using a 
Fisher’s trend test. Fisher’s allelic and recessive tests were performed using PLINK (see Web Resources). 
According to PLINK defaults, only females were included in the Fisher’s exact test for X chromosome variants. 
Comparison of Validation Rates. To determine if there were differences between the validation rates among 
different classes of functional variants, we took all autosomal variants that were seen in only a single sample in 
the initial sequencing cohort. These were considered to be the most vulnerable calls. We then selected from this 
group only the variants that were present in an individual that was genotyped with the iSelect array, and 
determined for each variant whether it had also been identified by the iSelect genotyping. Those identified were 
classed as validated, and we compared % validated among different functional groups. 
 
Results 
 
Association Testing. We performed whole exome (n=134) or whole genome sequencing (n=32) on 166 cases 
with schizophrenia and on 307 controls (n=256 exome and 51 genome) and followed this with Fisher’s Exact test 
to look for association with schizophrenia using both an allelic and a recessive model after excluding common 
variants. This resulted in a total of 337,312 variants, for which Bonferroni correction for multiple testing 
required a p< 1.5 x 10-7. At this p value threshold in a dataset of this size (focusing exclusively on rare variants), 
we would have limited power to detect anything but variants with an extremely high relative risk (Figure 1). As 
expected, no variant achieved the required level of significance in the initial sequence data. This is not surprising 
because variants that would show significance in this initial sequence dataset would have to have had effect 
sizes that would have been expected to have been identified in linkage analyses.  
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If we use a cutoff of p<0.05 instead, however, we are powered to identify variants over a much broader range of 
effect sizes and allele frequencies (Figure 1), although the majority of these variants will be false positives. We 
therefore adopted a two-stage strategy in which 1) the discovery cohort was used to identify a set of variants 
that is likely to be enriched for schizophrenia-associated variants (those with p<0.05 selected as described in 
methods; n=428), and 2) a follow-up sample of 2617 cases and 1800 controls was used to look for corroborating 
evidence of association. The original sequencing data were combined with the iSelect data to produce a final 
dataset of 2785 cases and 2120 controls. 
Because there were insufficient markers included to adjust for population stratification accurately, Fisher’s exact 
tests (for both recessive and allelic models) were performed on individuals of African and European descent 
separately, and a logistic regression using self-described race (including only those of European or African 
ancestry) was used to look for variants that associated in both ancestry groups. Using a Bonferroni correction for 
all original 337,312 variants, p< 1.5 x 10-7 was required for study-wide significance. The lowest p values in the 
combined dataset were 0.0003 (allelic) and 0.01 (recessive). The most significantly associated variants in the 
African American only analysis had p values of 0.0006 (allelic) and 0.0005 (recessive), and the most significant 
variants in Europeans were 5.9x10-6 (allelic) and 0.01 (recessive). The most strongly associated variant was a 
non-synonymous variant in AL589787.16 (HUGO:N/A, rs7098669) that was originally included because it showed 
association in the recessive model. This variant shows substantial variation in allele frequency across 
populations, and the association probably reflects population stratification. It is interesting to note, however, 
that this SNP lies within an open reading frame (C10orf90) found to contain two independent schizophrenia 
associations in the recent mega-GWAS, although the association did not hold up in the follow-up cohort of that 
study26. 
Evaluation of Genotypes Exclusive to Cases. Most very rare highly penetrant schizophrenia-associated 
genotypes would not be expected to show a significant association in a dataset of the size of our discovery 
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cohort. Such genotypes would be found exclusively in cases, but only in very small numbers. We therefore also 
followed up all genotypes that were present in two cases and no controls (n= 861) and a subset of those present 
in one case and no controls (n=4498; see Methods for selection criteria), as this dataset is likely to be enriched 
for very rare variants with high penetrance. Table 1 summarizes the iSelect outcome for the different categories 
of variants. Of the 4028 genotypes originally present in only a single case and successfully genotyped in the 
follow up, 1588 (39%) were seen in an iSelect control, and 1989 (49%) were seen in only one or no further cases. 
To further explore the frequency of these variants in controls, we referred to the Exome Variant Server, NHLBI 
Exome Sequencing Project (ESP), Seattle, WA [accessed January 2012]. Supplementary tables 1 and 2 show all 
case-specific variants and case-specific homozygotes, respectively.  
Some variants remained absent in all controls, and were found to be present in several additional cases (table 
2). The variant present in the most cases (n=5) is a non-synonymous mutation (ENST00000380099 g1882C>T; 
Arg628Cys) in KL [MIM 604824], a gene that acts mainly in the renal and cardiovascular systems27. However, KL 
has also been implicated in the regulation of vitamin D metabolism. Klotho deficient mice, for example, show 
degeneration of mesencephalic dopamine neurons28 and other aging phenotypes, such as hearing loss29, which 
can be rescued with a vitamin D deficient diet. Although KL has not been previously associated with 
schizophrenia to our knowledge, substantial evidence implicates alterations in vitamin D levels, especially 
deficiency, as a risk factor for schizophrenia that may also help to explain certain epidemiological findings, such 
as season of birth and latitude gradient effects on geographic differences in incidence and prevalence 30-32. In 
addition, prenatal vitamin D deficiency has been shown to have lasting changes in NMDA-mediated brain 
function in adult rats33. Other genes of interest with case-only variants include EPB41L1 [MIM 602879], SLC1A2 
[MIM 600300], STX4 [MIM 186591], HYDIN [MIM 610812], PCLO [MIM 604918] and ZNF804B [MIM:NA]. 
EPB41L1  encodes the erythrocyte membrane protein band 4.1-like N34, which co-localizes with AMPA receptors 
at excitatory synapses and is thought to mediate the interaction of the AMPA receptors with the cytoskeleton35. 
It has also been shown to be necessary for the formation of calcium waves in the mediation of neurite 
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formation36. A recent study of synaptic protein sequencing reported a de novo functional missense mutation in 
EPB41L1 in nonsyndromic intellectual disability37. SLC1A2 (aka (EAAT2, GLT1) encodes a glial high affinity 
glutamate transporter, and  is the major transporter in the forebrain38. Mice lacking Slc1a2 have spontaneous 
lethal seizures and are vulnerable to glutamate neurotoxicity after forebrain trauma39. STX4 directs membrane 
fusion at excitatory glutamatergic synapses, and is essential for normal dendritic spine morphology, retrograde 
synaptic signaling and long-term potentiation (LTP) at hippocampal synapses40. A frameshift mutation of Hydin 
causes recessively transmitted hydrocephalus in the mouse41. Additionally, a paralog of HYDIN is included in 
1q21.1 microdeletions and microduplications that have been associated with microcephaly, macrocephaly and 
neuropsychiatric disorders including schizophrenia16. PCLO encodes Picollo, which acts alongside Bassoon, 
Syntaxin, SNAP-25, and N-Cadherin, in the presynaptic active zone, a specialized region where synaptic vesicles 
dock and fuse42. Piccolo is upregulated in the nucleus accumbens in response to methamphetamine, and 
antisense suppression of Piccolo increases the behavioural response to amphetamine and causes synaptic 
accumulation of dopamine43. ZNF804B is a paralog of ZNF804A [MIM 612282], which has shown evidence in 
GWAS studies for an association with schizophrenia44. Some variants were present in both cases and controls 
but were homozygous only in cases (see supplementary table 2). Two variants were homozygous in 3 or more 
cases and absent in all controls, but they are both predicted to be benign.  
Interestingly, it was recently shown that loss-of-function mutations have a lower validation rate than other 
classes of variants 45. This is expected, because deleterious variants are likely to be less common than those with 
moderate or no function and thus, all else being equal, there is a lower prior that deleterious variants are real. 
We searched for a similar effect in our data, although we expected our validation rate in general to be higher 
because (i) we required high stringency for variants to be carried to follow up, and (ii) we looked almost 
exclusively at rare variants predicted to have strong functional effects, so the magnitude of the difference 
among them would be expected to be reduced. Nevertheless, we do see an attenuated effect as described by 
MacArthur et al. (2012), such that if we compare validation rates (as defined by a variant being genotyped on 
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the iSelect array) among types of variants the rates for very rare nonsense (76%, n=388) and essential splice 
variants (73%, n=221) are lower than for non-synonymous variants (86%, n=2826). 
Discussion  
In this large-scale report of sequenced schizophrenia genomes, we have looked for evidence for association of 
individual, rare, highly penetrant sequence variants in a discovery cohort of 166 cases and 307 controls and in a 
follow-up cohort of 2756 cases and 1932 controls. We found no significantly associated variants after Bonferroni 
correction for multiple hypothesis testing.  
Having found no significantly associated SNVs, we focused on variants that were present in more than one case 
and absent in controls. At least some of these may ultimately prove to be statistically associated with 
schizophrenia, even though each was individually too rare to reach study-wide significance in this dataset. We 
found a small number of variants that remain good candidates as individual schizophrenia-associated variants 
and are high priority for follow up studies. However, because of their low frequency, large collaborative studies 
will be required to provide statistically significant evidence for their association with schizophrenia. As an 
illustrative example, we can consider the top hit, a missense mutation in KL that was present in 5/2780 cases 
and absent in 7417 controls. Assuming that the frequency in cases remains at 0.18%, and that we had equal 
numbers of cases and controls, we would need to see about 23 more schizophrenia cases with this variant, 
requiring approximately 13,000 schizophrenia cases and controls, to obtain study-wide significance for this 
individual variant (p< 1.5 x 10-7).  
This study had 99% power to detect moderately rare (1-5%) variants with relative risks between 2 and 6. As 
some variants in this frequency range would have been poorly represented on GWAS chips46, and effect sizes in 
part of this range would have been difficult to detect consistently with linkage studies47, variants with these 
properties have not previously been systematically investigated on a genome-wide scale in relation to 
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schizophrenia. On the basis of our findings and those of previous studies, some possible genetic architectures 
for schizophrenia risk appear increasingly unlikely, including (i) a small number of highly penetrant loci 
explaining the majority of cases (linkage studies), (ii) common variants with low relative risks underlying most 
cases (GWAS), and (iii) so called “goldilocks alleles”, 48 or moderately rare variants with moderate RR explaining 
most cases (present study). This finding suggests that the majority of schizophrenia-associated variants will be of 
very low frequency and their association with schizophrenia will most readily be confirmed by their collective 
presence in genes associated with schizophrenia using collapsing methods and related approaches49-52, rather 
than by variant-specific frequency differences between cases and controls. 
These findings have a number of implications. First, a likely benefit of the 1000 genomes project will be novel 
GWAS arrays that extend to variants in the 1-5% frequency range. Our results suggest that the use of these 
arrays in relation to schizophrenia is unlikely to reveal significant associations for RRs above 2.  
Second, our data strongly suggest that genetic risk factors for schizophrenia are outside the range of what is 
easily detected in sample sizes of the sort used here. For example, although our power to detect variants with 
frequencies below one percent is low, if there were many risk factors near this frequency cutoff with modest 
effect sizes, we should have detected evidence for some of them. Thus, at least in terms of the relatively rare 
and high impact variants contributing to schizophrenia risk, the genetic architecture is one characterized by high 
locus heterogeneity, or high allelic heterogeneity, or, more likely, both. Beyond locus and allelic heterogeneity, 
the results could also be consistent with oligogenic, polygenic or epistatic models where effect sizes for 
individual variants are very modest, and the genotypes are reasonably penetrant only in combination. We did 
not explicitly test for such models given the current sample sizes. Considering the number of tests required for 
open screens of interacting variants (even limited to interacting pairs and restricting analyses to common 
variants), we suspect that such interactions will need to be identified secondarily to the identification of a main 
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effect, however small, for a single variant, or through testing of specific hypotheses analyzing small sets of 
variants in defined biological pathways.  
It is valuable to consider these observations in light of the example of CNVs. Copy number variants were the first 
type of rare variants that could be detected on a genome-wide scale. Moderately rare CNVs with RR from 2-25 
were immediately and definitively associated with schizophrenia risk across different cohorts and populations9; 
10; 17. Because other types of rare genetic variation, such as SNVs and indels, were not available for comparison, 
it was not possible to determine whether these properties were specific to large structural variants or were 
representative of rare schizophrenia-associated variants in general. Here, we have been able to systematically 
search for associated SNVs with similar relative risks that explain as high a proportion of cases as some of the 
CNV regions, and have failed to identify any.  
It is essential to appreciate that the schizophrenia-associated CNVs were detectable because recurrent mutation 
greatly increases the number of affected cases. Any given mutation event leading to a CNV appears to be 
responsible only for a few cases among closely related relatives10. If SNV mutations prove analogous, we would 
expect certain individual genes or gene pathways to associate with schizophrenia, although individual variants in 
those genes would not be frequent enough to reach statistical significance by themselves in the sample sizes 
used in our follow-up genotyping experiment. The clear implication is that collapsing methods that combine 
qualifying variants in individual genes, and/or much larger sample sizes will be required to find secure evidence 
of risk-conferring genes. Such a conclusion should not  necessarily discourage the prospects for gene discovery 
in schizophrenia, rather it suggests that the clearest path to discovery should focus on both significantly 
expanded samples sizes and sophisticated methods to appropriately combine qualifying variants affecting the 
same genes49-52. Thus, we propose two possible strategies, one that sequences a sufficiently large discovery 
cohort to prioritize genes in terms of their load of qualifying mutations, followed by sequencing of those genes 
of interest in additional samples , and/or a second that generates complete sequence data on 10,000 or more 
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case genomes. Significant findings from either approach will implicate particular genes as risk factors for 
schizophrenia, and these genes will hopefully converge on a limited number of pathways, thus providing 
valuable information about the genetic etiology of schizophrenia. Either way, only very rarely will an individual 
variant be determined to be causal in an individual schizophrenia case, thus limiting the scope for genetics in 
individual risk prediction.  
Two conclusions emerge from this study. First, multiple genetic variants must underlie the predisposition to 
schizophrenia. Current sequence data cannot determine whether risk alleles will affect tens, hundreds, or 
thousands of different genes as our power to distinguish allelic and locus heterogeneity in this study is limited. If 
locus heterogeneity were low, however, we would expect linkage data to have been more consistent in 
implicating a small number of genomic regions. On balance, therefore, the data appear to point toward both 
high locus and allelic heterogeneity. Second, the risk variants for schizophrenia will be rare, although we cannot 
determine from a study of this size just how rare individual pathological variants will be.  
The conclusions of this study must be tempered by a number of considerations. First, we analyzed only coding 
regions. It therefore remains possible that moderately rare regulatory variants with relatively strong effect sizes 
explain the majority of cases of schizophrenia. This would seem to be an unlikely model based on the prominent 
role of coding variants in Mendelian disorders, but will be tested in the near future as variants identified from 
whole-genome sequencing of individuals with schizophrenia are investigated in larger datasets. One example of 
a regulatory region that was not represented in this study was that around the microRNA MIR137 (miR-137), 
which was recently associated with schizophrenia through a “mega-GWAS” 26. It is also likely that some of the 
variants that we included as likely to be functional are in fact errors of reference-based mapping, and that other 
functional variants (e.g., nonsense mutations) were excluded from the analysis due to mismapping 45.  
Second, our initial analysis included cases from multiple populations, including Finns and African Americans. If 
rare schizophrenia-associated variants are population specific, power would be reduced by not focusing on 
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single ethnic or racial groups. We know from previous studies that different racial and ethnic groups share rare 
CNVs 17, but this could be because they are in hypermutable regions and thus the same structural changes arise 
multiple independent times, which is much less likely to be the case for SNVs. Although we performed separate 
analyses for samples of self-reported European and African ancestry, we were not able to control for population 
structure within these groups. Stratification usually acts to inflate test statistics, but the effect on power was 
expected to be modest. Additionally, existing methods are not effective for the type of structure caused by rare 
variants53. We therefore took the approach to be maximally inclusive in this exploratory study, and that any 
variants that were supported in the second stage would be further investigated in cohorts that are robust to the 
effects of population stratification, such as family-based studies, as suggested in ref 53. Finally, the discovery 
sample comprised mostly people with treatment resistant schizophrenia, who are a special population 
representing about 30% of people who meet DSM IV criteria for schizophrenia54. The replication sample had a 
much smaller percentage of treatment-resistant cases so there remains a possibility that real associated variants 
were not supported in the follow-up sample because they increase the risk for treatment-resistant 
schizophrenia specifically, but not for schizophrenia more generally.   
Our findings will aid in the interpretation of future small-scale sequencing studies. Here we have investigated 
almost all obvious functional variants in a set of 166 schizophrenia cases and have found no study-wide 
significant associations. Notably, the majority of non-private variants that were exclusive to cases in the 
discovery cohort were either seen in controls in the follow-up sample (60%), or were not seen in any further 
cases (23%). Thus, associations based on small-scale sequencing studies, however biologically enticing, must be 
interpreted with caution pending validation in larger follow-up studies. 
If the majority of variants occur at very low frequency, there are a number of potential investigative strategies. 
The most obvious and immediate strategy would be to use gene-based NGS approaches to comprehensively 
investigate candidate genes (e.g., from CNV studies or GWAS) in large datasets, as described above. This 
17 
 
approach would allow us to accurately gauge how much of the heritability of schizophrenia is explained by 
genes that have already been identified. We can also take advantage of the relatively small early sequencing 
datasets to identify a small number of promising candidate rare variants such as those presented here that 
continue to be absent in controls, for genotyping in larger datasets. Although the majority of these candidates 
will turn out to be false positives, potential insight into schizophrenia etiology is worth the cost if even one is 
statistically proven. Finally, rare variants can be investigated using family studies, using either segregation 
analyses in multiplex families or looking for de novo or recessive variants in sporadic cases. Although both of 
these approaches are likely to produce multiple candidate variants per family, with adequate control datasets 
and by comparing multiple families in collaborative efforts, it should be possible to identify either recurring 
variants or repeatedly disrupted genes that will ultimately prove to contribute to schizophrenia risk. 
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Figure 1. Range of relative risks and minor allele frequencies that are detectable with 99% power at p<0.05 and p<1.5 x 10-7 (corrected for all 
included variants) in a cohort of 166 cases and 307 controls. 
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Table 1. Summary of Outcomes for Variants by Original Inclusion Criteria 
Reason for original inclusion 
(n=5788) 
Failed or 
excluded 
Present in controls, p< 0.05 Absent in controls 
In African-
American
s only 
In white 
only 
In both 
ancestral 
groups 
In neither 
ancestral 
group 
In 0 
additional 
cases 
In 1 
additional 
case 
In >1 
additional 
case 
p<0.05 (n=428) Allelic 
(n=242) 
30 3 28 2 173 4 2 0 
recessive 
(n=186) a 
37 5 11 1 131 1 0 0 
in >1 case and 0 
controls (n=861) 
allelic 
(n=843) 
94 9 15 0 476 192 34 23 
recessive 
(n=18) a 
2 0 1 0 12 2 1 0 
in 1 case and 0 
controls 
(n=4498) 
allelic 
(n=4280) 
434 28 9 0 1443 1929 301 136 
recessive 
(n=218) a 
36 2 3 0 103 60 7 7 
 ap-values given for recessive tests; counts are for homozygous genotypes. 
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Table 2. SNVs Seen in Two or More Follow-up Schizophrenia Cases that were Absent in All Study Controls and Also Invariant in the NHLBI Exome 
Sequenced Cohort. A full list of variants, with further details, including those that were absent in our study but either seen in NHLBI controls or 
not covered in the NHLBI Exome Sequenced Cohort, can be seen in supplementary table 1.  
VARIANT 
(chr_hg18 
position_varian
t allele) 
Gene  
 
MIM 
Number Transcript 
(Ensembl 50_36l) 
RefSeq mRNA Annotated function;position 
of sequence and amino acid 
change 
Tot
al 
cas
es 
European 
American 
case 
counts 
(hom/het 
/ref) 
European 
American 
control 
counts 
(hom/het 
/ref) 
African 
American 
case 
counts 
(hom/het 
/ref) 
African 
American 
Control 
countsa 
(hom/het 
/ref) 
Other 
case 
counts 
(hom/h
et/ref) 
Other 
controlc
ounts 
(hom/h
et/ref) 
Total 
samples 
(NHLBI 
cohort) 
European 
Amerian 
samples 
(NHLBI 
cohort) 
African 
Amerian 
samples 
(NHLBI 
cohort) 
13_32533098_T KL 604824 
ENST00000380099 NM_004795.3 NS; c.1882C>T; p.Arg628Cys 
5 0/1/1564 0/0/1359 0/4/1186 0/0/679 0/0/30 0/0/82 5379 3510 1869 
19_2785443_A ZNF554 NA
ENST00000317243 NM_001102651.1 NS; c.1210G>A; p.Gly404Arg 
4 0/3/1561 0/0/1359 0/1/1189 0/0/679 0/0/30 0/0/82 5351 3508 1843 
20_34245584_G EPB41L1 602879 
ENST00000344237 - NS; c.59A>G; p.His20Arg 
4 0/4/1560 0/0/1359 0/0/1187 0/0/679 0/0/30 0/0/82 5379 3510 1869 
2_238150673_A RAB17 602206 
ENST00000264601 NM_022449.3 NS; c.401C>T; p.Thr134Met 
4 0/0/1565 0/0/1359 0/4/1186 0/0/679 0/0/30 0/0/82 5379 3510 1869 
21_44639800_T TRPM2 603749 
ENST00000397928 NM_003307.3 NS; c.1870G>T; p.Asp624Tyr 
4 0/3/1561 0/0/1359 0/1/1189 0/0/679 0/0/30 0/0/82 5376 3508 1868 
1_55290595_T PCSK9 607786 
ENST00000302118 NM_174936.3 NS; c.580C>T; p.Arg194Trp 
3 0/0/1565 0/0/1358 0/3/1187 0/0/679 0/0/30 0/0/82 5379 3510 1869 
11_111555378_
T 
BCDO2 611740 
ENST00000393032 NM_001037290.2 X; c.154C>T; p.Arg52* 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5379 3510 1869 
11_35290538_T SLC1A2 600300 
ENST00000395750 NM_001195728.2 NS; c.317G>A; p.Arg106His 
3 0/2/1563 0/0/1359 0/1/1189 0/0/679 0/0/30 0/0/82 5379 3510 1869 
12_12952740_A GPRC5A 604138 
ENST00000014914 NM_003979.3 NS; c.290G>A; p.Arg97His 
3 0/0/1565 0/0/1359 0/3/1187 0/0/679 0/0/30 0/0/82 5379 3510 1869 
15_41875227_T SERINC4 614550 
ENST00000299969 - Splice; c.918-1C>T;  
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5379 3510 1869 
16_1083724_C C1QTNF8 614147 
ENST00000328449 NM_207419.3 X; c.537C>G; p.Tyr179* 
3 0/3/1557 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5368 3500 1868 
16_30958421_A STX4 186591 
ENST00000313843 NM_004604.3 NS; c.761G>A; p.Arg254His 
3 0/1/1564 0/0/1359 0/2/1188 0/0/679 0/0/30 0/0/82 5379 3510 1869 
16_69543869_T HYDIN 610812 
ENST00000316490 - NS; c.6340G>A; p.Gly2114Arg 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 4650 3215 1435 
17_7769756_A KCNAB3 604111 
ENST00000303790 NM_004732.3 X; c.508C>T; p.Arg170* 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5379 3510 1869 
19_19506937_A AC011448.5 NA
ENST00000397179 NM_198537.3 NS; c.413G>A; p.Arg138Gln 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5167 3422 1745 
19_60041100_T KIR3DL3 610095 
ENST00000391729 - X; c.328C>T; p.Gln110* 
3 0/0/1559 0/0/1355 0/3/1186 0/0/679 0/0/30 0/0/82 5264 3418 1846 
2_32578230_C BIRC6 605638 
ENST00000261359 - NS; c.8497G>C; p.Glu2833Gln 
3 0/0/1542 0/0/1337 0/3/1187 0/0/679 0/0/29 0/0/75 5379 3510 1869 
3_114481460_A BOC 608708 
ENST00000355385 NM_033254.2 NS; c.2120G>A; p.Arg707His 
3 0/2/1563 0/0/1359 0/0/1190 0/0/679 0/1/29 0/0/82 5379 3510 1869 
3_42714733_A HHATL 614071 
ENST00000341477 - NS; c.325C>T; p.Arg109Cys 
3 0/1/1564 0/0/1359 0/0/1190 0/0/679 0/2/28 0/0/82 5379 3510 1869 
6_117745049_A ROS1 165020 
ENST00000368507 - NS; c.6067A>T; p.Met2023Leu 
3 0/0/1565 0/0/1359 0/3/1187 0/0/679 0/0/30 0/0/82 5379 3510 1869 
7_65077123_A GUSB 611499 
ENST00000345660 - X; c.916C>T; Arg305* 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5379 3510 1869 
7_82419591_T PCLO 604918 
ENST00000333891 - NS; c.8407G>A; p.Val2803Ile 
3 0/0/1512 0/0/1312 0/3/1186 0/0/679 0/0/29 0/0/80 5032 3389 1643 
7_86891201_A ABCB4 171060 
ENST00000394680 - NS; c.2168G>T; p.Gly723Val 
3 0/0/1565 0/0/1359 0/3/1187 0/0/679 0/0/30 0/0/82 5379 3510 1869 
7_88803894_A ZNF804B NA
ENST00000333190 NM_181646.2 NS; c.3662C>A; p.Ala1221Asp 
3 0/3/1562 0/0/1359 0/0/1190 0/0/679 0/0/30 0/0/82 5379 3510 1869 
a. No variant had an rs number; NS= non-synonymous, X=Nonsense 
